Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngen Biotech CoROCO:8279 +1.03%89 FCF Margin % is 10.54% as of Dec. 2025, which is 71% above its 10-year median of 6.16. GuruFocus rates ROCO:8279 with a GF Score™ of 89/100 and a GF Value™ of NT$158.15 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Syngen Biotech Co ranks better than 83.89% on this metric.
The historical rank and industry rank for Syngen Biotech Co's FCF Margin % or its related term are showing as below:
ROCO:8279'
s FCF Margin % Range Over the Past 10 Years
Min: -15.91 Med: 6.16 Max: 18.68
Current: 11.38
During the past 13 years, the highest FCF Margin % of Syngen Biotech Co was 18.68%. The lowest was -15.91%. And the median was 6.16%.
ROCO:8279's FCF Margin % is ranked better than 83.89% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs ROCO:8279: 11.38
Syngen Biotech Co FCF Margin % Related Terms
Syngen Biotech Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for Syngen Biotech Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8279 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Syngen Biotech Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngen Biotech Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syngen Biotech Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Syngen Biotech Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngen Biotech Co (ROCO:8279) has a FCF Margin % of 10.54% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Syngen Biotech Co and its competitors. This is 71% above median its historical median of 6.16. According to the industry distribution chart, Syngen Biotech Co ranks #153 out of 950 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Syngen Biotech Co's FCF Margin % too high?
Syngen Biotech Co's current FCF Margin % of 10.54% is 71% above median its 10-year median of 6.16. Based on the distribution chart, Syngen Biotech Co ranks #153 out of 950 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Syngen Biotech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syngen Biotech Co ranks #153 out of 950 companies for FCF Margin %. This places Syngen Biotech Co in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Syngen Biotech Co and its competitors. Syngen Biotech Co's current FCF Margin % is 10.54%, which is 71% above median its own 10-year median of 6.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$158.15, compared to a current price of NT$88.50 — trading 44% below its estimated fair value. The current FCF Margin % is 10.54%, which is 71% above median its 10-year median of 6.16. Syngen Biotech Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current FCF Margin % is 10.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?
Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued.
The current stock price of NT$88.50 is trading 44% below its estimated GF Value™ of NT$158.15.
GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:8279:
FCF Margin %: 10.54% (71% above median its 10-year median of 6.16)
GF Value™: NT$158.15 vs. price of NT$88.50 (44% below fair value)
No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
89GF Score
Get the complete analysis for ROCO:8279
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8279 has been successfully added to your 
